Research guides
Semax and Selank blend: what the research says
Two Russian-developed neuroactive peptides in one vial, each registered there and neither as a combination. What is published on each, and what it rests on.
Available in the catalogue
Supplied as research material. Sizes and pricing are on the product page. Availability is not a statement about what a compound does.
This blend pairs two peptides that come out of the same research tradition and are usually discussed together — which is not the same as having been studied together.
What is in the vial
Semax, an ACTH(4-10) analogue with a Pro-Gly-Pro tail, and Selank, a tuftsin-derived peptide with the same stabilising tail. Both are registered as medicines in Russia and neither holds a marketing authorisation in the EU, UK or US.
Why they get paired
Their reported effects are described as complementary rather than overlapping: Semax's literature centres on BDNF and the neurotrophin system, Selank's on GABAergic and serotonergic signalling and on anxiolytic activity without sedation. Two different targets, one broad area of interest.
There is also published human imaging work examining functional connectivity under both compounds, which is the closest the literature comes to treating them as a pair — and it is an imaging study of their effects, not a trial of a combined preparation.
The language problem, doubled
Both compounds have most of their literature published in Russian and not indexed where Western reviewers search. That means the English-language evidence base understates the work on each — and it also means that the absence of a published combination study is harder to interpret here than it would be for a compound whose literature is fully indexed.
The honest position: no combination study was found, the components are individually registered medicines in one jurisdiction, and neither of those facts substitutes for the other.
What studies reported
Each entry states what a study examined and the model it used. Nothing below describes an outcome for a person.
Everything below is drawn from published research, and each entry names the model the study used. Approval status varies by compound and by country, and nothing described here is supplied as a medicine or for use in a person.
Adverse and null findings reported
No dedicated safety study has been published for this compound. That is not a finding that none exists — it means the question has not been asked in print, and the gaps below say so.
What the research does not establish
An absence cannot be cited, so these are stated plainly. They are the part of the picture that silence would otherwise hide.
- No published study investigates this combination. Everything known about the contents of this vial comes from work on the individual components, tested separately.
- Both components have most of their literature published in Russian and not indexed in the databases Western reviewers search, so absence of a found combination study is weaker evidence of absence here than elsewhere.
- Neither component has a randomised controlled trial published in a Western-indexed journal, so the blend inherits two evidence bases that are thin in English rather than one.
- No published work establishes a basis for the ratio in which the two are combined.
- The published human imaging work examines the two compounds' effects on brain networks; it is not a trial of a combined preparation and should not be read as one.
- Analytical work on seized research-peptide preparations has repeatedly found material that did not match its label. For a two-component vial, identity is a question a certificate of analysis has to answer for both.
Common questions
- Why are Semax and Selank sold together?
- Because their reported effects are described as complementary — Semax around BDNF and the neurotrophin system, Selank around GABAergic and serotonergic signalling. They are frequently discussed together, which is not the same as having been studied together.
- Has the combination been studied?
- No published study of the combination was found. There is human imaging work examining both compounds' effects on functional connectivity, but that is not a trial of a combined preparation.
- Are Semax and Selank approved medicines?
- Both are registered as medicines in Russia, individually. Neither holds a marketing authorisation in the EU, UK or US, and the blend is not registered anywhere.
- Why does the Russian-language literature matter here?
- Because most of the work on both compounds is published in Russian and not indexed where Western reviewers search. The English-language record understates what exists, which makes an absence of found studies harder to interpret.
- Is this blend approved as a medicine?
- No. It is supplied here as a laboratory reagent for in-vitro research and not for human or veterinary use.
Compounds covered
The reference page for each compound this article discusses.
Related articles
- Semax: what the research says
An ACTH(4-10) analogue registered as a medicine in Russia and unknown to Western regulators. What the BDNF work reported, and why the English record looks thin.
- Selank (TP-7): what the research says
A tuftsin-derived anxiolytic registered as a medicine in Russia. Its defining reported property is what it lacks: sedation. The rodent evidence, and the limits.
- N-Acetyl Semax Amidate: what the research says
A terminally capped Semax with no literature of its own. What the capping is meant to do, and why every claim about it is borrowed from a different molecule.